TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
NCT05883176
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma by BCLC Stage
Interventions
DRUG:
Bevacizumab Biosimilar QL 1101
Sponsor
Sun Yat-sen University